

REMARKS

Status of the Claims

Claims 1-2, 4-8, 10-50 and 52-79 are currently pending in the application.

Claims 2, 4-8, 10-50, 52-53 and 55-79 are canceled without prejudice or disclaimer with entry of the above Amendment.

Claim 1 is amended with entry of the above Amendment.

Claims 80-84 are newly added with entry of the above Amendment.

Claims 1 and 80-84 remain under consideration with entry of this Response.

Summary

Claims 1-2, 4-8, 10-50 and 52-79 are pending in the application and were examined in the Office Action dated 17 March 2010. Applicants submitted a Supplemental Response under 37 C.F.R. §1.111 on 16 March 2010 which has been entered into the file but has not been reviewed by the Office. The Office has raised the following claim rejections: **(a)** claims 12 and 57 are rejected under 35 U.S.C. §112, second paragraph, as indefinite; **(b)** claims 1, 2, 4-7, 10-18, 29, 30, 46-50, 55, 57, 61, 63-68, 70, 71 and 73-79 stand rejected under 35 U.S.C. §102(b) as unpatentable over U.S. Patent No. 5,747,058 to Tipton et al. ("Tipton"); **(c)** claim 77 stands rejected under 35 U.S.C. §102(b) as unpatentable over U.S. Patent No. 6,312,717 to Molinoff et al. ("Molinoff"); and **(d)** claims 1, 2, 4-8, 10-31, 41-50, 55, 57-64, 68-76, 78 and 79 stand rejected under 35 U.S.C. §103(a) as unpatentable over Tipton. Applicants respectfully traverse all pending claim rejections for the following reasons.

Overview of the Amendment

Applicants, by way of the above claim amendment, have canceled claims 2, 4-8, 10-50, 52-53 and 55-79 without prejudice or disclaimer. Cancellation of these claims is not in acquiescence to any asserted rejection, and applicants expressly reserve their right to bring the claims again in another related application. Applicants have also amended

claim 1 to recite certain preferred embodiments of the invention and to substantially simplify the issues pending herein. In particular, claim 1 has been amended: to specify that the HVLCM is sucrose acetate isobutyrate present in the formulation at from 30 – 90 wt%; to recite that the rheology modifier is selected from a preferred group of molecules, and finally to recite that the formulation provides for prolonged drug release over at least an hour of time and further that the formulation is resistant to drug extraction in ethanol. Finally, new claims 80 – 84 have been added to recite dosage forms having a specified wt% of the network former (claim 80), to specify a particular network former (claim 81), to specify a certain preferred group of drugs (claim 82), to specify that the solvent is present in a specified wt% (claim 83), and to specify that the solvent is selected from a preferred group of molecules (claim 84). Support for the amendments to claim 1 and to new claims 80 – 84 can be found throughout the specification and claims as originally filed, for example at Paragraphs [0018], [0037 – 0038], [0040], [0045], [0048 – 0049], [0051], [0056], [0059 – 0060], [0062], [0065], [0070], [0072 – 0076], [0080 – 0081], and [00120 – 00129] of the Published Application; in original claims 7, 20, 50, 57 and 59; and in Figures 1 – 4 and 11. Accordingly, applicants submit that no new matter is added by way of the claim amendments and new claims, and the entry thereof is respectfully requested.

The Rejection under 35 U.S.C. §112, Second Paragraph

Claims 12 and 57 stand rejected under 35 U.S.C. §112, second paragraph, as indefinite. In particular, the Office has objected to the use of the tradename “MIGLIOL” in the claims. Correction was required. In response, applicants note that the subject claims have been canceled with the above Amendment, rendering the ground of rejection moot. In addition, the tradename does not appear in any of claims 1 and 80-84 that remain under consideration. Reconsideration and withdrawal of the rejection under 35 U.S.C. §112, second paragraph, is thus respectfully requested.

The Rejections under 35 U.S.C. §102

Claims 1, 2, 4-7, 10-18, 29, 30, 46-50, 55, 57, 61, 63-68, 70, 71 and 73-79 stand rejected under 35 U.S.C. §102(b) as unpatentable over Tipton. Applicants note that this is the same rejection that was initially asserted in the Office Action dated 11 September 2007 and then withdrawn in the Office Action dated 25 June 2009. In particular, the Office reasserts that Tipton disclosed individual elements that are found in applicants' recited composition, and then concludes that there is an anticipating composition ("the composition of Tipton") that would inherently possess applicants' recited properties/characteristics. Office Action at pages 4 and 5. This position is completely contrary to the Office's stated position on 30 June 2008, where the Office confirmed that Tipton "does not disclose one composition that has HVLCM, CAB, solvent and rheology modifier". See 30 June 2008 Office Action, page 7. Applicants once again respectfully traverse the rejection for the following reasons.

The Office's restated position is an entirely incorrect analysis under Section 102. In this regard, the case law is very clear regarding the requirements for anticipation of an invention when that invention combines elements from the prior art into a new combination. This is because the courts have consistently acknowledged that brand new elements and materials are rarely ever discovered and, accordingly, most inventions must necessarily be some combination of pre-existing elements. Thus, the courts have consistently instructed that a claim is anticipated only if each and every element as set forth in the claim is described in a single prior art reference, that is, the identical invention must be shown in the prior art reference in as complete detail as is contained in the claim (see, e.g., *Verdegaal Bros. v. Union Oil Co. of California*, 2 USPQ2d 1051 (Fed. Cir. 1987); and *Richardson v. Suzuki Motor Co.*, 9 USPQ2d 1913 (Fed. Cir. 1989)), and that the elements must be arranged as required by the claim (see, e.g., *In re Bond*, 15 USPQ2d 1566 (Fed Cir. 1990)). In addition, the courts have instructed that, for a recited combination, the identical invention is the express combination (not some different combination), and that if a reference fails to highlight a particular mixture or combination, among the many other mixtures disclosed, that reference fails to anticipate (*In re Kollman et al.* 201 USPQ 193 (CCPA 1979)). Furthermore, the courts have

instructed that, where one skilled in the art would have to choose judiciously from a number of different possible combinations from a prior art reference, that reference fails to anticipate (In re Sivaramakrishnan 213 USPQ 441 (CCPA 1982)). Finally, the basis on which anticipation is measured is whether or not the prior disclosure is an “enabled disclosure” and this is particularly important when a theory of inherency is being used, as is the case in the instant rejection. *In re Samour*, 197 USPQ 1 (CCPA 1978).

In order for Tipton to anticipate claims 1 and 80-84, that reference would have had to disclose applicants’ express mixture or combination, that is, a specific mixture containing all of applicants’ recited claim elements in their express combination (the identical invention must be shown, with all elements arranged as required by the claim). The Office has already acknowledged that this is simply not the case (see 30 June 2008 Office Action, page 7) and this failure is also clear from any proper reading of the Tipton reference. In this regard, the identical invention is the express combination (not some different combination) and since Tipton fails to highlight applicants’ particular mixture, among the numerous other mixtures that are actually disclosed therein, Tipton fails to anticipate applicants’ claims. Furthermore, since one would have to judiciously choose elements from judiciously chosen, unrelated lists of additives from Tipton to arrive at applicants recited combination – over any other of the enormous number of other possible combinations from that reference – Tipton simply fails to anticipate applicants’ claims. Tipton simply fails to provide an enabled disclosure of applicants’ expressly recited combination of elements, having applicants expressly recited performance characteristics.

For all of the foregoing reasons, then, the rejection under 35 U.S.C. §102(b) over Tipton is improper. Reconsideration and withdrawal of the rejection is thus earnestly solicited.

Claim 77 stands rejected under 35 U.S.C. §102(b) as unpatentable over Molinoff. Applicants respectfully traverse the rejection. Initially, applicants note that the subject claim has been canceled with the above Amendment, rendering the ground of rejection moot. In addition, the only similarity between Molinoff and the invention of claims 1 and 80-84 (that remain under consideration herein) is that they are pharmaceuticals.

However, Molinoff clearly fails to disclose an oral dosage form having applicants' required combination of elements and recited drug release performance / extraction resistance. Reconsideration and withdrawal of the rejection over Molinoff is thus respectfully requested.

The Rejection under 35 U.S.C. §103(a)

Claims 1, 2, 4-8, 10-31, 41-50, 55, 57-64, 68-76, 78 and 79 stand rejected under 35 U.S.C. §103(a) as unpatentable over Tipton. In particular, the Office asserts that Tipton discloses a composition, and that "the composition of Tipton would inherently possess the characteristics of [applicants' recited invention]." Office Action at pages 6 and 7. In support of this position, the Office has referred to various unrelated portions of the Tipton document, skipping variously around from column 2, to column 4, then column 8, then column 12, then claim 88, etc. The Office defends its position asserting that there would be a "strong suggestion to combine the disclosed components in one dosage form" since Tipton discloses all of the components of the claimed dosage form. Office Action at page 11. Applicants respectfully traverse the rejection for the following reasons.

Initially, applicants note that the Office has created an entirely circular argument that begins and ends with an improper assumption. In this regard, the Office has used the Tipton reference as a catalogue of separate parts, combining multiple, distinct teachings from Tipton to arrive at an artificial combination of unconnected elements which is then declared "the composition" of Tipton. The Office then turns the full circle by comparing this artificial combination ("the composition" of Tipton) to applicants' recited invention, supporting its combination on nebulous grounds such as an assertion that Tipton did not expressly teach that any one the disclosed elements should not be combined into a single composition (Office Action at page 11), or that Tipton teaches a variety of optional additives "and these additives modify the properties of the composition" (Office Action at page 13. The proper analysis should have looked to applicants' claimed combination and then demonstrated that Tipton somehow enabled that particular combination to the skilled person, pointing to specific technical rationale available from Tipton or existing in

the prior art to make that particular combination. However, the Office has failed to make the proper analysis. The Office has failed to provide a rational basis why one would want or need to combine certain specific elements from Tipton, picking and choosing among the various part catalogs, to somehow arrive at applicants' recited invention. In fact, the Office has had to skip from Tipton's general disclosure of controlled release compositions found in columns 7 – 10, to an unrelated and distinct specific disclosure of a mouthwash composition found in columns 11 and 12, and then skip to claim 88 just in order to find a sufficient number of individual elements to form the core of applicants' claimed combination. Given the differences between these various sections of the Tipton reference, applicants strongly contest the Office's position that such picking and choosing was obvious in light of Tipton (that is, applicants' recited invention as a whole was an obvious modification of the Tipton disclosure and that the skilled person would have recognized this particular combination and had a reasonable expectation for success for that combination), when there is simply no technical basis for this assertion. The sole basis that the Office has provided to support its piecemeal, hindsight reconstruction of applicants' specific combination is that Tipton teaches that additives can be added to pharmaceutical compositions as desired to modify the properties, and that Tipton did not expressly forbid combining applicants' recited elements.

Applicants respectfully submit that this line of reasoning is technically incorrect and fails to meet the minimum standard for obviousness. More particularly, applicants have disclosed and claimed a particular set of pharmaceutical excipients that are combined to provide an oral, controlled release pharmaceutical formulation suitable to provide for long term delivery (e.g., between 1-20 hours or greater) of potent and potentially dangerous drugs, where the subject formulations are also able to resist unwanted extraction of the entire drug dose as a result of simple extraction techniques such as those that can be performed using the commonly accessible solvent ethanol. These twin required performance characteristics of applicants' formulations are diametrically opposed requirements, where the skilled person understood that developing a composition having one feature (e.g., provide long term controlled delivery) would be expected to eliminate the other feature (e.g., resist extraction into ethanol), and *vice-*

versa. Accordingly, applicants' recited formulations provide unexpected and surprising results.

Initially, applicants submit that the Office has failed to provide persuasive reasoning (i.e., some sort of articulated reasoning with rational underpinning to support the legal conclusion of obviousness) to start with any of the compositions actually described by Tipton and then modify that starting composition to form applicants' expressly recited combination. Failure to provide such persuasive reasoning has consistently been found to support a finding of non-obviousness by the Federal Circuit applying the KSR standards for obviousness (*KSR Intern. Co. v. Teleflex, Inc.*, 127 S. Ct. 1727 (2007)). See, e.g., *Takeda Chem. Indus, Ltd. V. Alphapharm Pty., Ltd.*, 492 F.3d 1350 (Fed. Cir. 2007) (where the court found that, rather than identifying a predictable solution, the prior art disclosed a broad selection of compounds any of which could be selected for further investigation, and further that there was nothing in the prior art to narrow the possibilities, nor anything to suggest making the modifications that were necessary to arrive at the claimed compositions); *Ortho-McNeil Pharm., Inc. v. Mylan Labs, Inc.*, 520 F.3d 1358 (Fed. Cir. 2008) (where the court found that one of ordinary skill in the art would not have any reason to select among several unpredictable alternatives to produce the invention, and that, without any clue of potential utility of the claimed composition, one would have no reason to develop that composition in the first place – the court also noted that evidence of objective criteria showing non-obviousness, including unexpected results, were of particular importance); *Eisai Co., Ltd. V. Dr. Reddy's Labs, Ltd.*, 533 F.3d 1353 (Fed. Cir. 2008) (where the court found that a *prima facie* case of obviousness for a chemical compound begins with a reasoned identification of a lead compound, and that the record contained no reasons why the skilled artisan would have considered modification of a lead compound as an identifiable, predictable solution); and *Proctor & Gamble v. Teva Pharm.*, 566 F.3d 989 (Fed. Cir. 2009) (where the court found that one must determine whether, at the time of the invention, a person having ordinary skill would have had reason to attempt to make the claimed composition and a reasonable expectation of success in doing so, and that, to the extent an art is unpredictable, as the chemical arts often are, KSR's focus on 'identified, predictable

solutions' may present a difficult hurdle because potential solutions are less likely to be genuinely predictable, citing *Eisai, Id.*, and *KSR*). In fact, the Supreme Court itself has noted that it will often be necessary "to determine whether there was an apparent reason to combine the known elements in the fashion claimed by the patent at issue." *KSR Int'l Co. v. Teleflex Inc.*, 127 S. Ct. 1727, 1740 (2007).

Applicants' recited compositions, having their recited unexpected and surprising characteristics, cannot qualify as "identified, predictable solutions," that enjoy a reasonable expectation of success. Something that is unexpected and surprising cannot also be predictable and expected. The sort of apparent / persuasive reasoning required to support a showing of obviousness is not a simple matter of listing prior art, asserting some generalized motivation "to modify properties" with "additives", and then concluding with the stock phrase "therefore, to one skilled in the art it, would have been obvious to perform the claimed invention". Rather, there must be some apparent and rational basis for connecting unrelated disclosure from Tipton to produce applicants' specific, recited pharmaceutical formulation combinations, particularly in light of the unexpected and surprising performance features of those formulations. A mere generalized desire "to modify" chemical properties in a pharmaceutical product by "using additives" is simply not enough under a proper KSR analysis of obviousness in the chemical arts. See, e.g., *Innogenetics, N.V. v. Abbott Labs.*, 512 F.3d 1363 (Fed. Cir. 2008). Accordingly, the rejection of the claims as obvious over Tipton is improper.

In addition, applicants submit that a proper consideration of secondary considerations under a Graham Factor analysis provides further support for a conclusion of non-obviousness over Tipton. *Graham v. John Deere Co.*, 383 U.S. 1, 17-18, (1966). As noted by the Federal Circuit, the presence of secondary considerations such as long-felt but unsolved need, failure of others and unexpected results "may often be the most probative and cogent evidence [of non-obviousness] in the record." *Stratoflex, Inc. v. Aeroquip Corp.*, 713 F.2d 1530, 1538 (Fed. Cir. 1983). Post KSR, the Federal Circuit has confirmed the strength of such considerations, noting that evidence of objective criteria showing non-obviousness, including unexpected results, is of "particular

importance”. *Ortho-McNeil Pharm., Inc. v. Mylan Labs, Inc.*, 520 F.3d 1358 (Fed. Cir. 2008).

Applicants’ recited combination exhibits unexpected and surprising results in providing an oral dosage form that serves demonstrates both favorable drug release kinetics when ingested as intended, but also resists drug extraction for the dosage form when under a condition of abuse such as extraction into ethanol. These unexpected and surprising results are expressly recited in the claims and are clearly described by applicants, for example at Paragraph [0018], applicants state:

“A particular advantage of [the invention is] it provides an oral dosage form comprising a formulation ... effective to reduce the rate of extraction of the drug, for example with water, ethanol, or other solvents, while simultaneously providing desired drug release kinetics.”

Also, at Paragraph [0080], applicants state:

“The current invention also disclosed new and surprising interrelationships between the formulation ingredients, which resulted in unique and non-obvious formulation rheology, drug release kinetics, rate and extent of drug adsorption in vivo, and/or desirable abuse deterrence characteristics including reduced drug extractability, for example, by alcoholic or aqueous solutions.”

Furthermore, at Paragraph [0082] applicants state:

“The dosage forms of the invention show unexpectedly favorable drug-release kinetics” and at Paragraph [0084], applicants state “the drug-release kinetics ... can be seen to be both unexpected and favorable for delivery of drugs such as oxycodone.”

In addition, applicants demonstrate dosage forms having these combined properties in their working examples. See Paragraphs [0116 – 0119] and [0132 – 0135] and Figures 5 and 7 for drug release performance; and Paragraphs [0120 – 0129] and Figures 1-4 and 11 for extraction of drug into ethanol. These unexpected and surprising results are strong indicia of non-obviousness (in *KSR*, the Supreme Court, affirming *United States v. Adams*, held that the fact that elements worked together in an unexpected and fruitful manner supported the conclusion that *Adam*’s design was not obvious to those skilled in the art). *KSR, Id.*

Applicants' invention also answers a long-felt but unsolved need in the pharmaceutical arts. This unsolved need was discussed by applicants, for example at Paragraph [0005], where applicants state:

"Another challenge is to produce a dosage form ... that reduces the potential for drug abuse. In particular, opioids, CNS-depressants, and stimulants are commonly abused. According to a 1999 study by the National Institute on Drug Abuse (NIDA), and estimated 4 million people ... were (at the time of the study) using prescription drugs "non-medically." Of these, 2.6 million misused pain relievers, 1.3 million misused sedatives and tranquilizers, and 0.9 million misused stimulants."

At Paragraph [0013], applicants state:

"Solid dosage forms are particularly susceptible to abuse ... [a]ddicts ... grind the tablet to extract the drug into alcohol or water to make a concentrated injectable drug solution ... [t]hese well-known techniques for drug abuse have been used for many years with all manner of drugs."

At Paragraph [0014], applicants state:

"One particularly important example of a highly addictive drug that is commonly abused by ... alcohol and/or water extraction ... is Oxycodone ... [i]t has been alleged that Oxycontin® abuse has so far resulted in at least 120 deaths nationwide ... [o]verdose produces small pupils, slow breathing, dizziness, weakness, seizures, the loss of consciousness, coma, and sometimes death."

Then, at Paragraph [0015], applicants note:

"The above problems present a clear and long-felt challenge to drug manufacturers to produce drug dosage forms that also allow for desirable drug release kinetics and reduced potential for abuse."

Applicants submit that these clear public health and safety concerns have been at the forefront of public press for numerous years, have significantly increased in their magnitude on a yearly basis since the 1999 study described by applicants, and in fact were clearly urgent, yet completely un-met needs facing the drug industry prior to applicants' innovation to produce dosage forms that provide for both excellent controlled release kinetics when administered as intended, and strong resistance to extraction of the

drug when subjected to common methods of abuse, importantly extraction of the drug into ethanol (alcohol).


Accordingly, applicants respectfully submit that the Office has failed to establish a *prima facie* case of obviousness over Tipton. The Office has failed to show by clear and convincing evidence that a person of ordinary skill in the art would have had reason to attempt to make the specific composition recited in applicants' claims, having applicants' unique performance characteristics, and would have had a reasonable expectation of success in doing so. Accordingly, applicants respectfully submit claims 1 and 80 – 84 are patentable over Tipton. Reconsideration and withdrawal of the rejection under 35 U.S.C. §103(a) is thus earnestly solicited.

CONCLUSION

Applicants submit that the pending claims define an invention that is both novel and nonobvious over the cited art, and thus all claims are in condition for allowance. Acknowledgement of this by the Office in the form of an early allowance is thus respectfully requested. In addition, if the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, applicants invite the Examiner to contact the undersigned at (408) 777-4915.

The appropriate fee is either attached or authorized. However, if the Commissioner determines that an additional fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. **50-1953**.

Respectfully submitted,



Thomas P. McCracken
Registration No. 38,548

Date: 17 June 2010

For and on behalf of
DURECT CORPORATION
2 Results Way
Cupertino, CA 95014
Phone: (408) 777-4915
Fax: (408) 777-3577